CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Indivior swings into profit

By James Hester

12:46, 29 April 2021

Tablets on a desk

Indivior reported an 18% rise in first-quarter net revenue on Thursday, with strong growth from its opiate-addiction treatments and painkillers.

The US-headquartered pharmaceutical firm, which has its primary listing in the UK, said it had achieved earnings of $80m (£57.35m) in the first quarter versus a $163m loss for the same period in 2020.

An 18% jump in net revenue to $180m was primarily attributed to a higher contribution from its SUBLOCADE drug, which is used to treat adults suffering from addiction to opioid drugs, as well as growth from its opiate painkiller buprenorphine. Indivior also said its opiate addiction treatment SUBOXONE had seen relative market-share stability in the US.

"We have seen an encouraging start in FY 2021 with growth in net revenue, operating profit and cash from execution against our strategic priorities. Despite the ongoing impacts of COVID-19, SUBLOCADE injection achieved solid net revenue growth both on a sequential and year-over-year basis, and we expanded our Organised Health Systems platform to build the foundation for future growth,” said CEO Mark Crossley.

Revenue surge

Reported operating profit of $57m versus a $189m loss in the year-ago period reflected both higher net revenue and lower expenses, principally related to the direct-to-consumer advertising campaign for SUBLOCADE in the first quarter of 2020 as well as lower legal costs.

Net income of $80m includes an exceptional tax benefit of $36m recognised in relation to development credits for SUBLOCADE.

US100

18,291.90 Price
+0.040% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 1.8

US30

39,770.10 Price
+0.020% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 2.2

J225

40,321.50 Price
-0.460% 1D Chg, %
Long position overnight fee -0.0110%
Short position overnight fee -0.0112%
Overnight fee time 21:00 (UTC)
Spread 10.0

DE40

18,497.80 Price
-0.220% 1D Chg, %
Long position overnight fee -0.0221%
Short position overnight fee -0.0001%
Overnight fee time 21:00 (UTC)
Spread 1.5

US net revenue increased 25% to $131m while rest-of-world net revenue rose by just 2%.

What is your sentiment on UK100?

7962.8
Bullish
or
Bearish
Vote to see Traders sentiment!

Brightening outlook

Results for the second half of the year were expected to benefit from the rapid roll-out of coronavirus vaccines across the US.

“Looking ahead, we are seeing healthcare restrictions in the US begin to ease from the rapid pace of Covid-19 vaccinations, which supports our expectation of increased in-person interactions with healthcare practitioners in the second half of the year. As such, we are reiterating our FY 2021 base case guidance," added Crossley.

Indivior said it continued to anticipate long-term US market growth to be sustained in the high single-digit to low double-digit percentage range due to increased overall public awareness of the opioid epidemic and approved treatments, together with regulatory and legislative actions that have expanded opioid-use disorder treatment funding.

-
Sell
Spread
Chg%
Trade
go to page
+0.55%
go to page
+0.04%
go to page
+2.78%
go to page
+1.14%
go to page
+2.02%
go to page
+0.81%
go to page
+1.49%
go to page
+0.02%
go to page
-0.22%
go to page
-1.52%

Related topics

Rate this article

Capital Com is an execution-only service provider. The material provided in this article is for information purposes only and should not be understood as investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents and has not been prepared in accordance with the legal requirements designed to promote investment research independence. While the information in this communication, or on which this communication is based, has been obtained from sources that Capital.com believes to be reliable and accurate, it has not undergone independent verification. No representation or warranty, whether expressed or implied, is made as to the accuracy or completeness of any information obtained from third parties. If you rely on the information on this page, then you do so entirely at your own risk.

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading